Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2013 Aug;10(4):336-41.
doi: 10.1513/AnnalsATS.201210-088OC.

The safety of thoracentesis in patients with uncorrected bleeding risk

Jonathan T Puchalski  1 , A Christine Argento, Terrence E Murphy, Katy L B Araujo, Margaret A Pisani
Affiliations
Observational Study

The safety of thoracentesis in patients with uncorrected bleeding risk

Jonathan T Puchalski et al. Ann Am Thorac Soc. 2013 Aug.

Abstract

Background: Thoracentesis is commonly performed to evaluate pleural effusions. Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding. Frequently these medications are withheld or transfusions are performed to normalize physiological parameters before a procedure. The safety of performing thoracentesis without correction of these bleeding risks has not been prospectively evaluated.

Methods: This prospective observational cohort study enrolled 312 patients who underwent thoracentesis. All patients were evaluated for the presence of risk factors for bleeding. Hematocrit levels were obtained pre- and postprocedure, and the occurrence of postprocedural hemothorax was evaluated.

Measurements and main results: Thoracenteses were performed in 312 patients, 42% of whom had a risk for bleeding. Elevated INR, secondary to liver disease or warfarin, and renal disease were the two most common etiologies for bleeding risk, although many patients had multiple potential bleeding risks. There was no significant difference in pre- and postprocedural hematocrit levels in patients with a bleeding risk when compared with patients with no bleeding risk. No patient developed a hemothorax as a result of the thoracentesis.

Conclusions: This single-center, observational study suggests that thoracentesis may be safely performed without prior correction of coagulopathy, thrombocytopenia, or medication-induced bleeding risk. This may reduce the morbidity associated with transfusions or withholding of medications.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Bleeding risk categories (n = 130). Patients who underwent thoracentesis had between one and three risk factors for bleeding, as shown. INR = International Normalized Ratio.
Figure 2.
Figure 2.
The median change in hematocrit (%) in patients with and without a risk for bleeding during thoracentesis (n = 254).
See this image and copyright information in PMC

References

    1. Feller-Kopman D. Ultrasound-guided thoracentesis. Chest. 2006;129:1709–1714. - PubMed
    1. Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med. 2007;13:312–318. - PubMed
    1. Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg. 2007;84:1656–1661. - PubMed
    1. Gordon CE, Feller-Kopman D, Balk EM, Smetana GW. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med. 2010;170:332–339. - PubMed
    1. Grogan DR, Irwin RS, Channick R, Raptopoulos V, Curley FJ, Bartter T, Corwin RW. Complications associated with thoracentesis: a prospective, randomized study comparing three different methods. Arch Intern Med. 1990;150:873–877. - PubMed

Publication types

MeSH terms